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Abstract
Background: Sentinel node (SN) biopsy (SNB) detects clinically occult metastases of breast cancer and melanoma
in 20–30%. Wound infections, seroma and lymph edema occur in up to 10%. Targeted ultrasound (US) of the SN,
(with fine needle aspiration cytology (FNAC) if appropriate) has been investigated as a minimally invasive alternative,
but reported sensitivity rates are too low to replace SNB. Our hypothesis is that the use of a handheld gamma probe
concomitant with US may improve sensitivity.
Our aim is to provide an overview of the current literature on preoperative nodal staging of clinical N0
melanoma patients, report on a pilot, and present a study protocol for a minimally invasive alternative to the
SNB: Gamma probe and Ultrasound guided Fine needle aspiration cytology of the sentinel node (GULF trial).
Methods: The GULF trial is a multicenter open single arm observational trial. Newly diagnosed cT1b-4N0M0
cutaneous melanoma or cT1-3N0M0 breast cancer patients, aged >18 years, presenting for SNB are eligible. 120
patients will be included for preoperative targeted gamma probe guided US and FNAC of the SN. Afterwards all
patients proceed to surgical SNB. Primary endpoint is the sensitivity of FNAC. Secondary endpoints include SN
identification rate and the histopathological compatibility of Core Needle Biopsy and FNAC vs. SNB. Secondary
endpoints were investigated in a pilot with 10 FNACs and marker placements, and 10 FNACs combined with
Core Needle Biopsy.
Results: A pilot in 20 patients showed that SN identification rate was 90%, supporting the feasibility of this technique.
Discussion: There is broad experience with US (in combination with FNAC) prior to SNB, but sensitivity and specificity
are too low to completely abandon SNB. Promising alternative techniques potentially will replace SNB in the future but
more evidence is needed in the form of prospective studies. Accurate identification of the SN for US-FNAC has been
proven feasible in our pilot. When adequate sensitivity can be reached, US-FNAC provides a minimally invasive
alternative for the surgical SNB procedure.
Trial registration: The GULF trial is registered in the Netherlands Trial Registry (NTR), ID: NRT5193. May 1st 2015.
Keywords: Sentinel lymph node biopsy, Ultrasonography, Fine-needle biopsy, Melanoma, Breast Neoplasms, Minimally
invasive surgical procedures
* Correspondence: c.oudeophuis@erasmusmc.nl
1Department of Surgical Oncology, Erasmus MC Cancer Institute, Groene
Hilledijk 301, 3075 Rotterdam, EA, The Netherlands
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Oude Ophuis et al. BMC Cancer  (2017) 17:258 
DOI 10.1186/s12885-017-3236-2
Background
Sentinel node biopsy
With the introduction of sentinel node (SN) biopsy
(SNB) as a less invasive alternative to elective lymph
node dissection for melanoma and breast cancer with
clinically negative lymph nodes, this has become the
gold standard for adequate staging. Although less inva-
sive than an elective lymph node dissection, SNB is still
associated with some potential morbidity. Morbidity oc-
curs in up to 10% of patients; wound infections and ser-
oma are the most frequently seen complications [1, 2].
Rarely lymph edema is seen after SNB. Around 70–
80% of SNB’s are tumor negative after histological
assessment, these patients cannot benefit from the
SNB procedure. In that light the morbidity of a surgi-
cal SNB procedure is deemed considerable, and any
less invasive procedure, if accurate enough, would be
preferred.
The detection rate of submicrometastases has in-
creased considerably in the past decades; adaptation of
the melanoma and breast cancer SN sectioning proto-
cols and use of standard immunohistochemistry staining
enabled pathologists to detect even the smallest tumor
deposits accurately [3–8]. This has clear clinical implica-
tions; more patients are diagnosed as SN positive and
will be offered a completion lymphadenectomy (CLND)
[6, 8]. It is questionable whether this morbid surgical
procedure is justified in cases with minimal SN tumor
burden [9], as several retrospective melanoma studies
and recently the prospective DeCOG study have shown
that survival for this group of melanoma patients is simi-
lar to SN negative patients [10–13]. In breast cancer,
presence of isolated tumor cells (≤0.2 mm) or microme-
tastases (>0.2 ≤ 2.0 mm) is associated with a slightly
worse prognosis [7, 14], but its clinical relevance is de-
bated as well [15–17], and CLND is omitted in certain
groups of patients with a positive SN [18].
Prospective studies currently investigating the thera-
peutic value of CLND in melanoma are the EORTC-
1208MG (Minitub) [9], including patients with minimal
SN tumor burden only, and the MSLT2, which included
all SN positive patients [19]. Parallel to this, certain ad-
juvant therapy trials (EORTC 18071, EORTC 1325,
Combi-AD) recruit stage IIIA patients only in case of
≥1 mm SN tumor burden [20–22].
Primary results from the EORTC 18071 show that
SN positive patients benefit the most from adjuvant
treatment measured as recurrence free survival at
3 years [21, 22]. In this light, it remains worthwhile to
keep selecting patients for adjuvant therapy in trial
setting and/or CLND based on nodal staging, and a
cut-off for detection of (sub) micrometastases
(<1.0 mm) may aid in prevention of overtreatment in
low risk patients.
Ultrasound guided fine needle aspiration cytology
Ultrasound (US) guided fine needle aspiration cytology
(FNAC) or core needle biopsy (CNB) may provide a
good minimally invasive alternative to SNB. In breast
cancer patients screening US of the regional lymph node
basin is part of the preoperative staging process; this
way up to 17% of patients undergo axillary lymph node
dissection immediately and are spared a SNB [23, 24].
Melanoma patients do not routinely undergo a pre-
operative US of the regional lymph node basin, due to
previously reported poor identification rates of occult
lymph node metastases with US and FNAC [25, 26].
Several studies have been conducted in order to analyze
if US (with FNAC or CNB) can replace SNB, but thus
far reported sensitivity rates for US vary considerably,
ranging between 9 and 94% [27, 28].
For the current study we will focus on melanoma, as
the therapeutic value of both SNB and CLND are de-
bated, and alternatives for SNB are more limited for this
type of cancer.
In our search for a reliable and accurate minimally in-
vasive alternative to SNB for staging of clinical N0 mel-
anoma patients, we examined the current available
literature and performed a systematic search of all major
databases to explore whether other methods than US
guided FNAC may have proven adequate alternatives to
SNB.
Literature overview
All relevant studies on US imaging of regional lymph
nodes in melanoma patients scheduled for SNB are dis-
played in Table 1 (search details are given in Additional
file 1). Some of the studies mentioned in Table 1 are
overlapping; the studies from Voit et al. [29–33] concern
the same database with more inclusions over time. In
the studies that performed US prior to lymphoscintigra-
phy, sensitivity rates were low, ranging from 4.7% to
39%, and specificity rates were high, ranging from 86%
to 100%. Two studies did not mention the exact timing
of US in relation to lymphoscintigraphy; Hocevar et al.
reached a sensitivity and specificity of 71% and 84%, and
Testori et al. reached a sensitivity of 94% and 90%. In
the studies that performed a targeted US (i.e. US of the
marked “SN” area on the skin after lymphoscintigraphy),
sensitivity ranged from 22% to 100%, and specificity
ranged from 62% to 100% (Table 1).
Besides US and targeted US with FNAC prior to SNB,
several groups have focused on development of new im-
aging techniques for examination of the SN/lymph
nodes and detection of SN tumor deposits, such as
sonoelastography [34, 35], contrast enhanced US [36],
and multispectral optoacoustic tomography (MSOT)
[37] (Table 2). Sonoelastography measures tissue
consistency; which can be visualized on top of US
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Table 1 Studies of Ultrasound Imaging of Regional Lymph Nodes in Melanoma Patients Scheduled for Sentinel Node Biopsy
Author, year Study Design N US Setting FNAC/other
technique
Sens (%) Spec
(%)
PPV
(%)
NPV
(%)
Rossi [61], 2000 Not mentioned 69 Pre-lympho No 33 100 100 86
Rossi [25], 2003 Prospective,
monocentric
125 Pre-lympho FNAC if US
suspicious
US alone:
Not mentioned
- - -
US-FNAC: 39 100 100 85
Hocevar [62], 2004 Prospective,
monocentric
57 unknown FNAC if US
suspicious
US alone: 71 84 59 90
US-FNAC:
Not mentioned
- - -
Testori [63], 2005 Retrospective,
monocentric
88 unknown No 94 90 64 99
Starritt [64], 2005 Prospective,
monocentric
31 all SN + Post-lympho No NA NA NA NA
Voit [65], 2006 Prospective,
monocentric
127 Post-lympho FNAC if US
suspicious
US alone: 79 72 53 90
FNAC alone: 59 100 100 85
US-FNAC: 82 72 54 91
Van Rijk [26], 2006 Retrospective,
monocentric
107 Pre-lympho FNAC if US
suspicious
US alone: 34 87 - -
US-FNAC: 4.7 100 - -
Sibon [66], 2007 Prospective,
monocentric
131 Pre-lympho No 9 96 43 -
Kunte [67], 2009 Prospective,
monocentric
25 Pre- and
post-lympho
No 33 100 100 88
Voit [30], 2009 Prospective,
monocentric
400 Post-lympho FNAC if US
suspicious
65 99 93 92
Sanki [60], 2009 Prospective,
monocentric
716 Post-lympho No 33 97 60 88
De Giorgi [36], 2010 Prospective
monocentric
15 Post-lympho Standard CEUS CEUS: 100 62 55 100
Voit [31], 2010 Prospective
monocentric
400 Post lympho FNAC if US
suspicious
All Berlin criteria
combined: 82
80 52 94
Hinz [58], 2011 Prospective
monocentric
81 Pre and
post lympho
No 22 100 100 96
Chai [68], 2012 Retrospective
monocentric
325 Pre-lympho FNAC if US
suspicious
34 86 37 84
Marone [69], 2012 Prospective
monocentric
623 Pre-lympho No 15 100 100 87
Pilko [70], 2012 Retrospective
Monocentric
405 Pre-lympho FNAC if US
suspicious
Not mentioned - - -
Stoffels [71], 2012 Retrospective
Monocentric
221 Pre-lympho FNAC if US
suspicious
14 97 100 97
Hinz [72], 2013 Retrospective
Monocentric
20 Pre-lympho &,
pre PET-CT
No If US malig.
Direct LND
12 100 100 74
Ulrich [73], 2014
In German
Prospective
monocentric
800 Post lympho FNAC if US
suspicious
US-FNAC: 56 99 92 89
Voit [32], 2014 Prospective
monocentric
1000 Post lympho FNAC if US
suspicious
US alone: 71 - - -
US-FNAC: 51 99 99 89
Voit [33], 2016 Prospective
monocentric
1000 Post lympho FNAC if US
suspicious
US alone: 71 - - -
US-FNAC: 51 99 99 89
Overview of studies reporting on ultrasound imaging of regional lymph nodes in melanoma patients prior to sentinel node biopsy. Abbreviations: US ultrasound,
FNAC fine needle aspiration cytology, CEUS contrast enhanced ultrasound, Sens sensitivity, Spec specificity, PPV positive predictive value, NPV negative predictive
value, lympho lymphoscintigraphy, NA not applicable
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images using different color shades; red indicating soft
tissue, and blue indicating rigid tissue [34, 35]. As me-
tastases tend to be more solid than normal lymph node
tissue regions of interest for FNAC can be identified. For
contrast enhanced US an intravenous contrast agent is
applied to detect possible areas of hyperperfusion or hy-
poperfusion; indicating potential metastatic lesions [36].
These techniques reached a high sensitivity for identifi-
cation of SN metastases (Table 2).
Two recently developed techniques for improved SN
identification peri-operatively are SPECT-US [38, 39],
and near infrared light fluorescence imaging [40–44].
SPECT-US displays the location of a radio-active SN in
the US images; making it easier for the surgeon to locate
SN’s in anatomically challenging area’s such as the cer-
vical and occipital area; or to guide radiologists for
FNAC [38, 39]. Near infrared light fluorescence imaging
is conducted with Indocyanine green as tracer, which
can be combined with 99Tc nano-colloids to form a hy-
brid tracer [41]. Intraoperative identification is similarly
accurate to 99Tc-colloid; and particularly helpful for
SN localization in the cervical and occipital area, where
overprojection from the 99TC-colloid injection site is a
common obstacle. Preoperative (transcutaneous) SN
identification has reached lower identification rates,
due to the limited penetration depth of the fluorescent
tracer [45].
Summarizing, few US imaging studies have used a
method to accurately identify the SN prior to US exam-
ination and FNAC. This may have contributed to lower
than expected sensitivity rates for detection of SN me-
tastases in studies where this was not applied. It explains
why to date no alternative method for SN staging has
been adopted in daily clinical practice, and the need for
such a method remains.
Rationale for a new trial
SN identification
To overcome the problem of suboptimal identification
of the SN, we hypothesize that use of a handheld gamma
probe (Geiger teller) to detect the SN post lymphoscinti-
graphy may further aid the radiologist in accurately
identifying the SN for ultrasound guided FNAC. Sev-
eral pilot studies have been performed using this tech-
nique in breast cancer patients; correct localization of
the SN occurred in 75% - 100% [46–49]. This formed
the rationale for the GULF Trial (Gamma probe and
Ultrasound guided Fine needle aspiration cytology of
the sentinel node).
Cytology or histology?
In order to reach the sample size needed for proof of
concept with accurate power and within an acceptable
term, both melanoma patients and breast cancer patients
will be included in the GULF trial. The SN procedure is
uniformly applied for both melanoma and breast cancer,
and breast cancer patients may equally benefit from a
minimally invasive alternative for the SN. All patients
will undergo FNAC. Since metastatic size may have clin-
ical implications for breast cancer patients [18], a subset
of 10 breast cancer patients will undergo CNB addition-
ally after FNAC. This allows for a comparison of results
between CNB, FNAC and SNB.
Hypotheses GULF trial
We hypothesize that a sensitivity of 90% with a 95% con-
fidence interval of 80% - 100% is achievable. Secondly,
we expect that a SN identification rate of more than 75%
is feasible.
Study aims
 To present a study protocol for a minimally invasive
alternative to the sentinel node biopsy (GULF trial),
with as primary objective to determine whether an
acceptable sensitivity for US and gamma probe
guided FNAC can be achieved.
 Secondary objective is 1) the identification rate
of the SN and 2) the histological results of CNB
versus FNAC and versus SNB.
Prior to starting the GULF-trial, we had to prove the
concept of adequate identification of the SN. A pilot
Table 2 Pilot studies on novel techniques for pre-operative non-invasive detection of melanoma metastases in lymph nodes
Author, yr Topic No. of patients Technique Sens (%) Spec (%)
Hinz [72], 2013 Elastography 36 US + power Doppler: 81 76
Elastography: 91 76
Combined: 95 76
Ogata [35], 2014 Elastography 12 US: 77 57
Elastography: 100 71
Stoffels [37], 2015 MSOT and indocyanin green 20 MSOT 100 48.6
Overview of pilot studies investigating non-invasive detection of melanoma lymph node metastases
Abbreviations: yr. year, Sens sensitivity, Spec specificity, US ultrasound, MSOT multispectral optoacoustic tomography
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study focusing on the adequate detection rate of the SN
was conducted.
Pilot
After approval of the Ethical Review Board a pilot was
performed in 20 patients presenting at the Erasmus MC
Cancer Institute. All patients underwent gamma probe
guided US-FNAC after written informed consent. In the
10 first melanoma patients additional metallic marker
placement (O-Twist-Marker, BIP) was performed after
local infiltration of the skin and surrounding tissue with
1-10 mL lidocaine 2%. Correct identification of the SN
was assessed by examining the excised SN (s) on pres-
ence of the marker. Separately, in the first 10 breast can-
cer patients CNB was performed after FNAC with a 14G
needle, after local infiltration similar to marker place-
ment. CNB was done for assessment of concordance
with FNAC results and to detect potential superiority of
either technique.
All patients proceeded to OR for SNB, which was per-
formed according to the triple technique: preoperative
99Tc lymphoscintigraphy <24 h prior to surgery, intra-
dermal injection of patent blue near the primary tumor
site prior to first incision, and peroperative use of a
handheld gamma-probe to locate SN (s) [50, 51], Lymph
nodes were considered SN when radioactive and/or blue.
A marker was retrieved from the SN in 9 out of 10 pa-
tients; which meant the SN identification rate was 90%.
CNB samples were investigated on presence of lymphoid
tissue. This was present in 6 out of 10 patients. 40% of
CNBs was not representative. In comparison: FNAC
color staining was representative in 19 out of 20 patients
(95%), and FNAC immunohistochemistry staining was
representative in 14 out of 20 patients (70%).
During the pilot study no safety issues occurred. In
the second enrolled study patient none of the 2 placed
markers were found at histopathological examination of
the SN and in another patient only 1 of 2 placed
markers was found. A detailed shoulder X-ray confirmed
the markers were still in situ in both patients. In the lat-
ter patient the X-ray images were suggestive of marker
displacement towards mamma tissue; this was probably
due to intraoperative displacement of the marker during
SN removal.
Considering the positive results from this pilot, the
study will be continued with an expansion of the pilot
population in order to reach a sufficient sample size ac-
cording to the presented study protocol.
Methods
GULF design
Patients with a newly diagnosed cT1b-4N0M0 cutaneous
melanoma or cT1-3N0M0 breast cancer presenting at
the outpatient clinic of the Erasmus MC Cancer
Institute, and the Netherlands Cancer Institute – Antoni
van Leeuwenhoek (only melanomas) will be assessed for
inclusion. All patients will undergo US and gamma
probe guided FNAC of the SN. The pilot patients re-
ceived additional marker placement (n = 10) for identifi-
cation purposes, or additional CNB (n = 10) for
assessment of potential benefit of CNB (i.e. histology
and size measurement possible) (Fig. 1).
Study population
Inclusion criteria
Age ≥ 18 years, new diagnosis of cT1b-4N0M0 cutane-
ous melanoma or cT1-3N0M0 breast cancer.
Prior to start of any study related procedure, written
informed consent must be given according to ICH/GCP
and national legislation.
Exclusion criteria
Clinically suspect lymph node, other known malignancy
with potential to disseminate to axillary or groin lymph
Fig. 1 Study Flowchart GULF Trial
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node basins, prior lymph node biopsy, no SN visible at
lymphoscintigraphy/not identifiable with gamma probe.
Study procedures
US-FNAC
All patients will be admitted to the surgical ward on
the day of surgery. First, a lymphoscintigram <24 h
prior to SNB will be performed, as is standard proced-
ure. Following successful lymphoscintigraphy (i.e. SN
(s) is/are visible) the study procedures can start. A dedi-
cated radiologist will perform US imaging of the lymph
node basin where a SN or multiple SNs was/were iden-
tified by lymphoscintigraphy. The exact location of the
SN (s) will be determined using a handheld gamma
probe, and by combination with US; the assumed SN
(s) will be visualized (being a visible lymph node at the
center of the hotspot found with the gamma probe).
FNAC will be performed of all visualized assumed SN
(s). In case of multiple SNs in one lymph node basin or
multiple draining lymph node basins with an SN in
every basin (for instance a melanoma on the back
draining to both axilla and groin), FNAC will be per-
formed of all lymph nodes pointed out as primary tier
SN by the nuclear medicine specialist. For FNAC 1–4
cortical samples will be taken. Whenever additional
clearly suspect lymph nodes are visible, the radiologist
will perform FNAC from these nodes as well, as is
standard of care. All samples will be transported to the
pathology lab for analysis. US findings will be recorded
according to the Berlin morphologic Criteria to create
uniformity in recording per center [30]. After FNAC,
all patients will proceed to the operating room for SNB
according to standard procedure (as described in the
Pilot section). Lymph nodes were considered SN when
radioactive and/or blue. No diagnostic procedure or
treatment is postponed or elongated. No additional
visits to the outpatient clinic are required.
Endpoints
Primary endpoint: Primary outcome is the sensitivity of
gamma probe and US guided CNB or FNAC.
Secondary endpoints: Secondary outcome is 1) the
identification rate of the SN 2) the histological results of
CNB versus FNAC and versus SNB.
Ad 1) an identification rate of at least 75% is deemed
acceptable (concordant with literature). This has been
proven feasible in the pilot study.
Statistical considerations
Sample size and accrual
Based on retrospective data, the prevalence of metastatic
SNs is expected to be 30%. Our gold standard is the
histological outcome of SNB (absence or presence and
size of metastases in the SN). Submicrometastases (i.e.
<0.1 mm at any site or 0.4 mm subcapsular) in melan-
oma patients, and isolated tumor cells (i.e. ≤0.2 mm) in
breast cancer patients will be considered negative: a
negative FNAC is accepted in these cases. Based on pre-
vious reports, we expect to find around 10% of these
submicrometastases and isolated tumor cells in both
melanoma and breast cancer patients [52, 53]. Consider-
ing this, the maximum achievable sensitivity of FNAC
will be 90%. For this sensitivity, and a 95% confidence
interval of 80–100% (With a two-sided significance level
α = 0.05 and power 1 – β = 0.8), the required sample
size is 116 considering a 30% prevalence of metastatic
SNs. Around 3% of patients are expected to have a nega-
tive lymphoscintigram: the sample size will be increased
to 120 patients.
With an average accrual rate of 60 patients per year,
maximum accrual will be met at 2 years post start of
study.
Statistical analysis plan
The main analysis addressing the primary endpoint will
be performed after inclusion of all 120 patients. No in-
terim analysis is planned for this endpoint.
Ethical considerations
This study has been approved by the Erasmus MC
medical-ethical committee. The study will be conducted
according to the principles of the Declaration of Helsinki
and in accordance with national and regional legislation,
guidelines, regulations and acts.
Discussion
Currently SNB is the most important staging procedure
for clinically N0 melanoma patients, especially in the
light of trial participation for adjuvant therapies based
on N-status [20, 21, 54]. The therapeutic role of SNB
for melanoma is still under debate [55–57]. Considering
the fact that this is a surgical staging procedure associ-
ated with complications in up to 10% of patients, our
group sought to investigate a more minimally invasive
alternative.
The ongoing improvement of imaging techniques (i.e.
more accurate and detailed US imaging) and increased
experience with FNAC renders combined US-FNAC as
a high potential minimally invasive alternative for surgi-
cal SNB [31, 32]. Correct transcutaneous identification
of the SN forms the main obstacle for broad application
of this technique as this is key in obtaining reliable
FNAC.
The current study aims to give an overview of the
current melanoma literature, report a pilot and present a
study protocol for a minimally invasive technique to in-
vestigate the SN using gamma probe guided US-FNAC.
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Overview of the literature
The studies presented provide evidence that it is difficult
to detect clinically occult lymph node metastases in mel-
anoma patients, and although some studies have
achieved high sensitivity and specificity rates, these re-
sults have not been reproduced by other groups. There
are many differences between the reported studies;
namely retrospective vs. prospective study setting; US
prior to lymphoscintigraphy vs. targeted US after lym-
phoscintigraphy; the number of persons performing US
and their expertise; variation in US morphology criteria
used to discriminate between benign and suspicious or
malignant lymph nodes; and use of FNAC or not. Al
these factors will have contributed to the outcome of
these studies. It is interesting to see that sensitivity rates
are low in the studies that performed an US of the entire
lymph node basin without knowing the location of the
SN (s), but that even in the studies were targeted US of
the SN area was applied, sensitivity rates could be as low
as 22% [58] and as high as 82% [31] or even a perfect
100% [36] as well. Thompson et al. proposed a possible
explanation for these disparate results; many of the
micrometastases present in SNs are too small to be de-
tected by the US-equipment used [59, 60]. However,
Voit et al. demonstrated that it was possible to success-
fully perform a FNAC in a lesion as small as 0.4 mm.
Nevertheless, most smaller SN metastases will be over-
looked by US and/or missed by FNAC. The question is
if this has any clinical implications.
As long as US-imaging is limited by a detection limit,
and alternative imaging techniques are tested in pilot
settings, the need for a reliable, minimal invasive easy to
perform and replicate method to assess SN status re-
mains. Hence the presentation of the GULF trial study
protocol here.
Pilot
Our pilot results show that correct identification of the
SN for FNAC was possible in 90%, and that the sampled
material was representative in 95% of FNAC samples.
CNB was representative in only 60%. This confirms that
the described technique for targeted US-FNAC of the
SN is feasible. CNB will not be added to the study pro-
cedure considering the low rate of representative tissue
in the pilot phase.
If an acceptable sensitivity can be achieved for FNAC,
patients can proceed to undergo radical lymph node dis-
section immediately in case of positive FNAC, bypassing
the SNB procedure. When the FNAC sample is negative,
surgeons can choose to perform a SNB or continue with
only surgical excision of the primary tumor and moni-
toring of potential lymph node involvement at follow up
visits. This way up to 80% of patients eligible for SNB
can be spared this invasive procedure and the risk of
morbidity related to this procedure. Furthermore, for
melanoma patients this would mean that general
anesthesia is no longer needed, as WLE can be per-
formed under local anesthesia. Ultimately operative
nodal staging may become completely obsolete.
Conclusions
The literature on pre-operative assessment of regional
lymph nodes with US in clinically N0 melanoma patients
is disparate. Targeted US of the SN area in combination
with FNAC or other new techniques has potential to be-
come a minimally invasive alternative for the SNB, how-
ever, findings need to be replicated in prospective
clinical trials first. A pilot with gamma probe guided
US-FNAC show that accurate SN identification in up to
90% of patients is feasible. Our group presents a study
protocol of the Gamma probe and ULtrasound guided
Fine needle aspiration cytology of the sentinel node Trial
(GULF trial) as a potential improvement to the reported
US-FNAC techniques and ultimately even a possible re-
placement of the SNB.
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